Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arun Kanakkanthara

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Trends in Cell Biology|December 30, 2023
An ATM D-compartmentalization in DNA damage responseAnjali Prasad, Arun Kanakkanthara
Cancers|July 3, 2020
Beyond the Paclitaxel and Vinca Alkaloids: Next Generation of Plant-Derived Microtubule-Targeting Agents with Potential Anticancer ActivityDangquan Zhang, Arun Kanakkanthara
Cancer Treatment Reviews|August 21, 2012
MicroRNAs: novel mediators of resistance to microtubule-targeting agentsArun Kanakkanthara, John H Miller
Biochimica Et Biophysica Acta. Reviews on Cancer|August 8, 2021
βIII-tubulin overexpression in cancer: Causes, consequences, and potential therapiesArun Kanakkanthara, John H Miller
Biochimica Et Biophysica Acta. Reviews on Cancer|March 9, 2026
Mitochondrial metabolic vulnerabilities in high-grade serous ovarian cancerAnjali Prasad, Scott H Kaufmann, Arun Kanakkanthara
Molecular Cancer Therapeutics|December 20, 2011
βII-tubulin and βIII-tubulin mediate sensitivity to peloruside A and laulimalide, but not paclitaxel or vinblastine, in human ovarian carcinoma cellsArun Kanakkanthara, Peter T Northcote, John H Miller
Natural Product Reports|February 13, 2016
Peloruside A: a lead non-taxoid-site microtubule-stabilizing agent with potential activity against cancer, neurodegeneration, and autoimmune diseaseArun Kanakkanthara, Peter T Northcote, John H Miller
Bioorganic & Medicinal Chemistry|March 22, 2014
Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule functionJessica J Field, Arun Kanakkanthara, John H Miller
Anti-Cancer Agents in Medicinal Chemistry|May 16, 2012
Cytoskeletal alterations that confer resistance to anti-tubulin chemotherapeuticsArun Kanakkanthara, Paul H Teesdale-Spittle, John H Miller
Cancer Letters|May 13, 2014
Potential role of tubulin tyrosine ligase-like enzymes in tumorigenesis and cancer cell resistanceViswanath Das, Arun Kanakkanthara, Ariane Chan, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Trends in Cell Biology|December 30, 2023
An ATM D-compartmentalization in DNA damage responseAnjali Prasad, Arun Kanakkanthara
Cancers|July 3, 2020
Beyond the Paclitaxel and Vinca Alkaloids: Next Generation of Plant-Derived Microtubule-Targeting Agents with Potential Anticancer ActivityDangquan Zhang, Arun Kanakkanthara
Cancer Treatment Reviews|August 21, 2012
MicroRNAs: novel mediators of resistance to microtubule-targeting agentsArun Kanakkanthara, John H Miller
Biochimica Et Biophysica Acta. Reviews on Cancer|August 8, 2021
βIII-tubulin overexpression in cancer: Causes, consequences, and potential therapiesArun Kanakkanthara, John H Miller
Biochimica Et Biophysica Acta. Reviews on Cancer|March 9, 2026
Mitochondrial metabolic vulnerabilities in high-grade serous ovarian cancerAnjali Prasad, Scott H Kaufmann, Arun Kanakkanthara
Molecular Cancer Therapeutics|December 20, 2011
βII-tubulin and βIII-tubulin mediate sensitivity to peloruside A and laulimalide, but not paclitaxel or vinblastine, in human ovarian carcinoma cellsArun Kanakkanthara, Peter T Northcote, John H Miller
Natural Product Reports|February 13, 2016
Peloruside A: a lead non-taxoid-site microtubule-stabilizing agent with potential activity against cancer, neurodegeneration, and autoimmune diseaseArun Kanakkanthara, Peter T Northcote, John H Miller
Bioorganic & Medicinal Chemistry|March 22, 2014
Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule functionJessica J Field, Arun Kanakkanthara, John H Miller
Anti-Cancer Agents in Medicinal Chemistry|May 16, 2012
Cytoskeletal alterations that confer resistance to anti-tubulin chemotherapeuticsArun Kanakkanthara, Paul H Teesdale-Spittle, John H Miller
Cancer Letters|May 13, 2014
Potential role of tubulin tyrosine ligase-like enzymes in tumorigenesis and cancer cell resistanceViswanath Das, Arun Kanakkanthara, Ariane Chan, et al.
Pageof 3